Project Grant R01CA285515
Award Date
8/16/24
Completion Date
7/31/29
Dollars Obligated
$359K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
This $116,720 federal Project Grant award, provided by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program), will fund research to investigate the molecular basis of the interactions between the protein ABI1 and the androgen receptor (AR) in prostate cancer. The award will be used by the Research Foundation for the State University of New York, doing business as Upstate Medical Center, to conduct biophysical studies to elucidate how ABI1 binds to AR and affects its DNA...
The National Cancer Institute (NCI) awarded a $581,381 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to the Sloan-Kettering Institute for Cancer Research. The 5-year grant, effective June 5, 2025, will fund research to investigate the role of microhomology-mediated end-joining (MMEJ) in mitosis and its impact on drug resistance in cancer. The key products of this research will be a better understanding of DNA damage repair pathways and how they contribute...
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) will support research at Weill Medical College of Cornell University to investigate the role of the androgen receptor (AR) in both normal prostate cell function and prostate cancer development. The $564,543 award, effective March 1, 2025 through February 28, 2030, will enable the research team to determine the factors that mediate the switch between AR's normal, growth-suppressive...
The National Cancer Institute (NCI) awarded a $238,722 Project Grant under the Cancer Research Manpower (CFDA 93.398) federal grant program to the Sloan-Kettering Institute for Cancer Research in New York. The grant, awarded on August 18, 2025, will fund research to investigate the role of mutagenic DNA repair mechanisms, such as microhomology-mediated end joining (MMEJ), in driving acquired drug resistance in persister cancer cells. The research aims to define the specific mechanisms by which...
This Project Grant award of $656,304 from the National Cancer Institute's (NCI) Cancer Biology Research program (CFDA 93.396) supports comprehensive research at Weill Medical College of Cornell University to better understand the fundamental biological mechanisms underlying cancer development, progression, and potential interventions. The research aims to: (i) determine how nuclear accumulation of GSK3, upon suppression of mTORC1 signaling, regulates chromatin remodeling and DNA damage repair;...
The National Cancer Institute (NCI), under the Cancer Research Manpower (CFDA 93.398) Federal Grant Program, awarded a $163,364 Project Grant to The Research Foundation for the State University of New York, doing business as Stony Brook University. The grant, awarded on September 27, 2024, supports a research project titled "Mechanistic Studies of the NRF2-Methylosome Interaction in Lung Cancer." The research aims to biochemically characterize the functional binding partners of the...
This $3,787,956.00 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research by New York University School of Medicine to investigate and target replication stress in small cell lung cancer (SCLC). The research aims to: 1) understand how the SLFN11 gene impacts chemotherapy response in SCLC subtypes, 2) study how replication stress response pathways and modulators regulate chemosensitivity, and 3) develop strategies to target replication...
This federal Project Grant award, totaling $635,033, was provided by the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) to The Johns Hopkins University. The award will fund research to advance understanding of the genetic basis of a recently recognized cancer-prone syndrome caused by long telomere length. The key objectives are to identify additional novel genetic mechanisms for this "long telomere syndrome," define their role in familial cancer...
The federal Project Grant award F31CA295091 is funded by the National Cancer Institute (NCI), under the Cancer Research Manpower (CFDA 93.398) program. The $119,922 award supports research to investigate the role of the Fanconi Anemia (FA) pathway in driving a chromosomal abnormality called chromothripsis, which is frequently observed in cancer genomes. The research aims to comprehensively identify regions of micronucleated chromosomes undergoing FA pathway processing during mitosis, and to...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training program (CFDA 93.859) provides $680,400.00 to The University of Texas M.D. Anderson Cancer Center to conduct research on the link between replication fork protection and the innate immune response. The key objectives of this 4-year project are to: (1) delineate how stalled replication fork degradation activates innate immune signaling, (2) determine the role of...